• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Galera Therapeutics, Inc. - Common Stock (NQ:GRTX)

0.1450 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Galera Therapeutics, Inc. - Common Stock

News headline image
Halper Sadeh LLC is Investigating Whether LEG, AVNS, SEM, GRTX are Obtaining Fair Deals for their Shareholders
April 22, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
April 14, 2026
From Halper Sadeh LLC
Via Business Wire
News headline image
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
April 14, 2026
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
December 31, 2024
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Announces Board Approval of Complete Liquidation and Dissolution
August 14, 2024
Company reports second quarter 2024 financial results 
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
May 13, 2024
Company’s evaluation of potential strategic alternatives progresses with goal to maximize stockholder value 
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Adopts Limited Duration Stockholder Rights Agreement
May 03, 2024
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
March 28, 2024
Company continues to evaluate strategic options to maximize shareholder value 
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
November 14, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
October 31, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
September 18, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
August 14, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
August 09, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
June 05, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
May 18, 2023
Rucosopasem in clinical development to augment the anti-cancer efficacy of stereotactic body radiation therapy 
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
May 11, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Expands Commercial Leadership Team
May 01, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
March 10, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
March 08, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
February 15, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
February 15, 2023
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
December 12, 2022
NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patients 
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera to Present at Piper Sandler Annual Healthcare Conference
November 22, 2022
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
November 09, 2022
From Galera Therapeutics
Via GlobeNewswire
News headline image
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
October 26, 2022
From Galera Therapeutics
Via GlobeNewswire
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
December 21, 2021
Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the... 
Via FinancialNewsMedia
Ongoing R&D Leading to Discovery of More Efficient Therapies for Acute Myeloid Leukemia Therapeutics
December 15, 2021
Palm Beach, FL – December 15, 2021 – FinancialNewsMedia.com News Commentary – Acute Myeloid Leukemia (AML) is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also... 
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap